Article - 27/10/2014 Takeda GmbH in Singen – pharmaceutical development and production under one roof From stomach protection agents to drugs for the treatment of respiratory distress in preterm infants – Singen-based Takeda GmbH plays an important role as a competence centre for drugs in liquid and semi-solid dosage form within the Japanese pharmaceutical company’s global network. Besides the production of around 68 million packages per year, the company’s production site in Singen also focuses on drug development. The company’s CMC Centre…https://www.gesundheitsindustrie-bw.de/en/article/news/takeda-gmbh-in-singen-pharmaceutical-development-and-production-under-one-roof
Press release - 05/12/2011 Flexible Rack Systems Sort Molecules Researchers of Karlsruhe Institute of Technology (KIT) and Ruhr-Universität Bochum (RUB) have developed a flexible and efficient new process for the separation of enantiomers. Enantiomer separation is indispensable for the production of many pharmaceuticals. In their process, the scientists use porous molecular frameworks (MOFs) that are assembled in layers on solid substrates using a specifically developed method. The results have now been…https://www.gesundheitsindustrie-bw.de/en/article/press-release/flexible-rack-systems-sort-molecules
Press release - 14/05/2008 Vetter strengthens management team Vetters top management team is once again complete. As of June 1st 2008 Peter Soelkner will be heading a number of divisions at the Ravensburg-based company which specialises in the aseptic filling of prefilled injection systems. His new tasks will include Global Key Account Management Corporate Marketing Supply Chain Management and Project Management.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-strengthens-management-team
Press release - 03/12/2009 ELARA Pharmaceuticals receives EUR 4.6 Million funding ELARA Pharmaceuticals GmbH, a biotech company focused on the development of drugs for the treatment of different cancers, announced today the closing of a € 2.6 million Series A financing round, which will trigger an additional € 2 million from the BMBF GOBio and the Biotechnologie Rhein-Neckar (BioRN) Spitzencluster programs, leading to a total funding of € 4.6 million. https://www.gesundheitsindustrie-bw.de/en/article/press-release/elara-pharmaceuticals-receives-eur-4-6-million-funding
Article - 11/05/2008 New strategy against cervical cancer The German Cancer Research Centre and the Spanish company Chimera Pharma SL have signed an exclusive licensing and cooperation agreement. The two partners will develop a therapeutic vaccine against cervical cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/new-strategy-against-cervical-cancer
Press release - 04/11/2010 Nycomed to acquire of majority stake in Guangdong Techpool Bio-Pharma Nycomed today announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-to-acquire-of-majority-stake-in-guangdong-techpool-bio-pharma
Article - 28/07/2008 25 amino acids against avian influenza About a year ago Prof. Dr. Martin Schwemmle and his team at the University Hospital of Freiburg discovered a new starting point in the fight against the H5N1-virus. In the meantime the scientists are working together with the company Pike Pharma to develop a compound.https://www.gesundheitsindustrie-bw.de/en/article/news/25-amino-acids-against-avian-influenza
Press release - 19/11/2008 Review BIO-EUROPE 2008 The 14th annual edition of BIO-Europe which toke place in Mannheim strengthened its claim to being the worlds largest stand-alone partnering event with the participation of 1250 biotech pharma and professional service organizationsa and 190 company presentations.https://www.gesundheitsindustrie-bw.de/en/article/press-release/review-bio-europe-2008
Article - 06/12/2008 Strategic alliance between DKFZ and Bayer The German Cancer Research Centre and Bayer Schering Pharma AG signed an agreement to establish a strategic research alliance. The partners will invest a total of 3.5 million euros in cooperative cancer research over the next two years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/strategic-alliance-between-dkfz-and-bayer
Article - 06/05/2008 Vetter clients can concentrate fully on their core business The Ravensburg-based company Vetter Pharma-Fertigung GmbH & Co. KG is one of the leaders in biopharmaceutical contract manufacturing. We spoke with Max Horn, who has been with the company since 1981 and was appointed Managing Director in 2002.https://www.gesundheitsindustrie-bw.de/en/article/news/vetter-clients-can-concentrate-fully-on-their-core-business
The Baden-Württemberg healthcare industry The pharmaceutical industry Baden-Württemberg is Germany’s largest pharma location. In addition to industry giants such as Roche, GlaxoSmithKline and Boehringer Ingelheim, Baden-Württemberg is home to a large number of small- and medium-sized pharmaceutical companies and biotech companies with pharmaceutical research and development.https://www.gesundheitsindustrie-bw.de/en/location/pharma
Press release - 20/10/2009 2nd Science to Market Conference The second Science to Market Conference took place in Hannover, Germany, on October 6 – 7, 2009. The aim of the conference was the promotion of cooperation between academia and industry in the area of pharmaceutical biotechnology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/2nd-science-to-market-conference
Press release - 16/11/2015 The Baden-Württemberg healthcare industry – a strong economic power (Stuttgart – 16th November 2015) BIOPRO Baden-Württemberg has just published its latest analysis of the Baden-Württemberg healthcare industry including comprehensive facts and figures. Baden-Württemberg continues to be one of the top locations for medical technology, pharma and biotechnology in Germany. https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-baden-wuerttemberg-healthcare-industry-a-strong-economic-power
Press release - 09/02/2011 Nycomed to acquire Colombian company Farmacol Nycomed signs an agreement for the acquisition of Laboratorios Farmacol S.A. located in Colombia to further grow its presence in the Latin American region. Farmacol S.A., a Colombia based pharmaceutical company, has a strong presence in the areas of gastroenterology, respiratory and gynaecology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-to-acquire-colombian-company-farmacol
Press release - 03/09/2010 Vetter opens new sales office in suburban Chicago Vetter is combining its U.S. activities in the emerging pharmaceutical and biotechnology region of Illinois: Vetter has opened a new sales office in suburban Chicago to focus on its strategy of U.S. growth and expansion.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-opens-new-sales-office-in-suburban-chicago
Article - 14/10/2011 Vetter - a world market leader: “We put ourselves in our clients’ shoes" We talked with Peter Soelkner Managing Director of Vetter Pharma International GmbH. Soelkner has been with Vetter since 2008. Prior to his current position Soelkner was the head of Key Account Management at Vetter before going on to work for Sartorius Stedim Biotech USA. The sales specialist has a chemical engineering degree and an MBA from Columbia University NY.https://www.gesundheitsindustrie-bw.de/en/article/news/vetter-a-world-market-leader-we-put-ourselves-in-our-clients-shoes
Press release - 12/11/2009 SYGNIS reports on second quarter 2009/2010 Heidelberg, November 10, 2009 – SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today published its financial results for the second quarter and the first half of the fiscal year 2009/2010, which ended on 30 September 2009.https://www.gesundheitsindustrie-bw.de/en/article/press-release/sygnis-reports-on-second-quarter-2009-2010
Press release - 30/01/2017 ChemCon celebrates 20th anniversary ChemCon GmbH, service provider for custom development and custom manufacturing of active pharmaceutical ingredients (APIs) and fine chemicals, based in the Innovationspark (innovations park) Freiburg, Germany, celebrates its 20th anniversary. On January 29 in 1997, Dr. Raphael Vogler (CEO) and Dr. Peter Gockel (CSO), both graduates from the Albert-Ludwigs-University Freiburg, signed the partnering contract to found ChemCon. Today they count 90…https://www.gesundheitsindustrie-bw.de/en/article/press-release/chemcon-celebrates-20th-anniversary
Press release - 13/04/2021 Evotec’s BRIDGE “beLAB2122” leverages academic innovation from our region Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.https://www.gesundheitsindustrie-bw.de/en/article/press-release/evotecs-bridge-belab2122-leverages-academic-innovation-our-region
Press release - 28/09/2009 No sign of a crisis – biopharmaceutical services providers geared to further investment Vetter Pharma Fertigung a Ravensburg-based specialist in the production of aseptically pre-filled injection systems is strengthening its commitment to the North American market. Laupheim-based Rentschler Biotechnologie a contract research organisation that has been continuously expanding since 2006 has further investment plans.https://www.gesundheitsindustrie-bw.de/en/article/press-release/no-sign-of-a-crisis-biopharmaceutical-services-providers-geared-to-further-investment
Article - 13/09/2016 Catalent – galenics experts from Schorndorf Pharmaceutical and biotechnology companies are working intensively on the discovery and development of new drugs for the efficient and safe treatment of diseases. However, before drugs are authorised for treating humans and animals, they have to be made into a form that is acceptable. That is where a company called Catalent Pharma Solutions, with a facility in Schorndorf in the south of Germany, comes in.https://www.gesundheitsindustrie-bw.de/en/article/news/catalent-galenics-experts-from-schorndorf
Press release - 27/06/2019 Velabs Therapeutics Announces €3 Million Series B Financing to Advance its Functional Antibody Screening Programme Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, today announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional antibodies against diseases with poor treatment options. Further details of the financing round were not disclosed.https://www.gesundheitsindustrie-bw.de/en/article/press-release/velabs-therapeutics-announces-eur3-million-series-b-financing-advance-its-functional-antibody-screening-programme
Article - 14/06/2011 Retinitis pigmentosa: a new form of cell death What form of cell death do the photoreceptors of people suffering from retinitis pigmentosa undergo and how can their degeneration be prevented or delayed with pharmaceutical substances? Dr. Paquet-Durand from the Institute for Ophthalmic Research in Tübingen is working to resolve these questions.https://www.gesundheitsindustrie-bw.de/en/article/news/retinitis-pigmentosa-a-new-form-of-cell-death
Press release - 28/06/2011 Ulcerative colitis: Lipid Therapeutics announces start of Phase IIb clinical trial Lipid Therapeutics, a biotechnology company, announced today that it has initiated a Phase IIb clinical trial with its lead product LT-02 in patients with ulcerative colitis. Lipid Therapeutics received approval for this multi-center, international trial from the authorities in Germany and Lithuania and is awaiting approval in Romania. Patient enrollment has already started in Germany and Lithuania.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ulcerative-colitis-lipid-therapeutics-announces-start-of-phase-iib-clinical-trial
Article - 10/06/2014 Mathematical models for predicting cellular signalling pathways The micrometre-sized cells in organisms are biological systems in which countless vital processes take place. However little is yet known about most of these cellular metabolic chains because they interact with each other in a complicated manner. The research carried out by junior professor Nicole Radde and her doctoral student and engineer Patrick Weber from the Institute for Systems Theory and Automated Control IST at the University of…https://www.gesundheitsindustrie-bw.de/en/article/news/mathematical-models-for-predicting-cellular-signalling-pathways